Read the evidence
Peptide library
Browse evidence records, source dates and reading questions.
Policy context
The October 30, 2026 Federal Register notice announces draft interim guidance for certain peptide bulk substances under section 503A. Draft guidance is nonbinding; it is not drug approval, a permanent 503A bulks-list decision or a section 503B pathway. HHS may reconsider enforcement policy as safety or quality information changes.[2][4]
11 profiles
MetabolismSemaglutideApproved productRead profile →MetabolismTirzepatideApproved productRead profile →MetabolismLiraglutideApproved productRead profile →MetabolismDulaglutideApproved productRead profile →MetabolismRetatrutideInvestigationalRead profile →MetabolismCagrilintideInvestigationalRead profile →HormonesTesamorelinApproved productRead profile →Sexual healthBremelanotideApproved productRead profile →SkinCopper tripeptide-1Topical cosmeticRead profile →Muscles and jointsBPC-157Not FDA-approvedRead profile →HormonesIpamorelinNot FDA-approvedRead profile →